Efficacy of newer medications for treating depression in primary care patients

American Journal of Medicine

Volumn 108, Issue 1, 2000, Pages 54-64

  Mulrow, Cynthia D ^a,b   Williams Jr , John W ^a,b   Chiquette, Elaine ^a,b   Aguilar, Christine ^a,b   Hitchcock Noel, Polly ^a,b   Lee, Shuko ^a,b   Cornell, John ^a,b   Stamm, Karen ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMISULPRIDE; ANTIDEPRESSANT AGENT; ATOMOXETINE; AURONIX; BROFAROMINE; CITALOPRAM; DENIBAN; DOPAMINE RECEPTOR BLOCKING AGENT; FELSINOXAN; FEMOXETINE; FENGABINE; FLUOXETINE; FLUVOXAMINE MALEATE; GEPIRONE; HYPERICUM PERFORATUM EXTRACT; INDALPINE; IPSAPIRONE; ISOPULSAN; KIRA; LITOXETINE; MEDIFOXAMINE; MILNACIPRAN; MINAPRINE; MIRTAZAPINE; MOCLOBEMIDE; MOLCAMINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PLACEBO; REBOXETINE; RITANSERIN; SEDARISTON; SEROTONIN UPTAKE INHIBITOR; SOLAMID; SULPIRIDE; TANDOSPIRONE; TOLOXATONE; TREWILOR; TRICYCLIC ANTIDEPRESSANT AGENT; UMORIL; UNCLASSIFIED DRUG; VENLAFAXINE; VILOXAZINE; VITALOPRAM;

ANXIETY; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DYSTHYMIA; HUMAN; LITERATURE; META ANALYSIS; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSION; DEPRESSIVE DISORDER; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; EVIDENCE-BASED MEDICINE; GABA AGENTS; HUMANS; HYPERICUM; MONOAMINE OXIDASE INHIBITORS; PHYTOTHERAPY; PLANTS, MEDICINAL; PRIMARY HEALTH CARE; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS; UNITED STATES;

EID: 0033964499     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00316-2     Document Type: Review

References (50)

1. Greenberg P.E., Stiglin L.E., Finkelstein S.N., Berndt E.R. Depression a neglected major illness . J Clin Psychiatry. 54:1993;419-424.
2. Hays R.D., Wells K.B., Sherbourne C.D., Rogers W., Spritzer K. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry. 52:1995;11-19.
3. Simon G., Ormel J., VonKorff M., Barlow W. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry. 152:1995;352-357.
4. Depression Guideline Panel. Depression in primary care; vols. 1 and 2. Detection and diagnosis. Treatment of major depression. US Department of Health and Human Services, 1993.
5. North of England Evidence Based Guideline Development Project. The choice of antidepressants for depression in primary care. Centre for Health Services Research, 1998.
6. Muñoz R.F., Hollon S.D., McGrath E., Rehm L.P., VandenBos G.R. On the AHCPR depression in primary care guidelines further consideration for practitioners . Am Psychol. 49:1994;42-61.
7. Cooper-Patrick L., Crum R.M., Ford D.E. Characteristics of patients with major depression who received care in general medical and specialty mental health settings. Med Care. 32:1994;15-24.
8. Cerrahoglu L., Cogalgil S., Senel K., Turkmen M.B. The effects of antidepressive therapy in fibromyalgia syndrome. Fiz Tedavy Rehabil Derg. 19:1995;212-216.
9. Thase M.E., Trevidi M.H., Rush A.J. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 12:1995;185-219.
10. Berkey C.S., Hoaglin D.C., Mosteller F., Colditz G.A. A random-effects regression model for meta-analysis. Stat Med. 14:1995;395-411.
11. Sharp S. sbe23 meta-regression . Stata Tech Bull. 42:1998;16-22.
12. Sharp S., Sterne J. sbe16 meta-analysis . Stata Tech Bull. 38:1997;9-14.
13. Galbraith R. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 7:1988;889-894.
14. Patris M, Bouchard JM, Bougerol T, et al. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996;11:129-136.
15. Ekselius L, Von Knorring L, Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997;12:323-331.
16. Tylee A, Beaumont G, Bowden MW, Reynolds A. A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Prim Care Psychiatr 1997;3:51-58.
17. Corne S.J., Hall J.R. A double-blind comparative study of fluoxetine and dothiepin in the treatment of depression in general practice. Int Clin Psychopharmacol. 4:1989;245-254.
18. Hutchinson D.R., Tong S., Moon C.A., Vince M., Clarke A. Paroxetine in the treatment of elderly depressed patients in general practice a double-blind comparison with amitriptyline . Int Clin Psychopharmacol. 6:(suppl 4):1992;43-51.
19. Moon C.A., Vince M. Treatment of major depression in general practice a double-blind comparison of paroxetine and lofepramine . Br J Clin Pract. 50:1996;240-244.
20. Doogan DP, Langdon CJ. A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. Int Clin Psychopharmacol 1994;9:95-100.
21. Moon C.A., Jesinger D.K. The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice. Br J Clin Pract. 45:1991;259-262.
22. Kragh Sorensen P, Muller B, Andersen JV, Buch D, Stage KB. Moclobemide versus clomipramine in depressed patients in general practice. A randomized, double-blind, parallel, multicenter study. J Clin Psychopharmacol 1995;15(4 suppl 2):24S-30S.
23. Beaumont G., Gringras M., Hobbs F.D., et al. A randomised, double-blind, multi-centre, parallel-group study comparing the tolerability and efficacy of moclobemide and dothiepin hydrochloride in depressed patients in general practice. Int Clin Psychopharmacol. 7:1993;159-165.
24. Wheatley D. Minaprine an anticholinergic-free antidepressant? Results of a controlled trial of mianserin . Br J Psychiatry. 155:1989;106-107.
25. Wheatley D. Minaprine in depression. A controlled trial with amitriptyline. Br J Psychiatry. 161:1992;113-115.
26. Rosenberg C, Damsbo N, Fuglum E, Jacobsen LV, Horsgard S. Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study. Int Clin Psychopharmacol 1994;9(suppl 1):41-48.
27. Skrumsager B.K., Jeppesen K. Femoxetine and amitriptyline in general practice a randomized double-blind group comparison . Pharmacopsychiatry. 19:1986;368-377.
28. Lingjaerde O., Jorgensen J., Storen R., et al. A double-blind comparison of moclobemide and doxepin in depressed general practice patients. Acta Psychiatr Scand. 92:1995;125-131.
29. Christiansen P.E., Behnke K., Black C.H., Ohrstrom J.K., Bork Rasmussen H., Nilsson J. Paroxetine and amitriptyline in the treatment of depression in general practice. Acta Psychiatr Scand. 93:1996;158-163.
30. Lecrubier Y, Bourin M, Moon CA, et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 1997;95:485-93.
31. Boyer P., Lecrubier Y. Atypical antipsychotic drugs in dysthymia placebo controlled studies of amisulpride versus imipramine versus amineptine . Eur Psychiatry. 11:(suppl 3):1996;135S-140S.
32. Ravindran A.V., Jude R., Hunter B.N., Bray J., Morton N.H. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine study group. J Clin Psychiatry. 58:1997;112-118.
33. Moon CA, Jago W, Wood K, Doogan DP. A double-blind comparison of sertraline and clomipramine in the treamtent of major depressive disorder and associated anxiety in general practice. J Psychopharmacology 1994;8:171-176.
34. Laws D., Ashford J.J., Anstee J.A. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr Scand. 81:1990;185-189.
35. Aylward M., Maddock J., Dewland P.M., Lewis P.A. Sulpride in depressive illness. Adv Biol Psychiatr. 7:1981;154-165.
36. Barge Schaapveld D.Q.C.M., Nicolson N.A., van der Hoop R.G., DeVries M.W. Changes in daily life experience associated with clinical improvement in depression. J Affect Disord. 34:1995;139-154.
37. Dahl L.E., Lundin L., le Fevre Honore P., Dencker S.J. Antidepressant effect of femoxetine and desipramine and relationship to the concentration of amine metabolites in cerebrospinal fluid. A double-blind evaluation. Acta Psychiatr Scand. 66:1982;9-17.
38. Evans M., Hammond M., Wilson K., Lye M., Copeland J. Placebo-controlled treatment trial of depression in elderly physically ill patients. Int J Geriatr Psychiatry. 12:1997;817-824.
39. Geisler A, Mygind S, Knudsen OR, Sloth-Nielsen M. Ritanserin and flupenthixol in dysthymic disorder: a controlled double blind study in general practice. Nord J Psychiatry 1992;46:237-243.
40. Kivela S.L., Lehtomaki E. Sulpiride and placebo in depressed elderly outpatients a double-blind study . Int J Geriatr Psychiatry. 2:1987;255-260.
41. Simon G.E., VonKorff M., Heiligenstein J.H., Revicki D.A., Grothaus L., Katon W., Wagner E.H. Initial antidepressant choice in primary care effectiveness and cost of fluoxetine vs tricyclic antidepressants . JAMA. 275:1996;1897-1902.
42. Canadian Coordinating Office for Health Technology Assessment. Selective serotonin reuptake inhibitors (SSRIs) for major depression. Part I: evaluation of the clinical literature. CCOHTA Report 1997 3E, 1997.
43. Hotopf M., Hardy R., Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants a meta-analysis and investigation of heterogeneity . Br J Psychiatry. 170:1997;120-127.
44. Mulrow C, Williams J, Chiquette E, et al. Newer pharmacotherapies for depression. Psycho Pharm Bull 1999;34:409-795.
45. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995;310:1433-1438.
46. Montgomery S.A., Henry J., McDonald G., et al. Selective serotonin reuptake inhibitors meta-analysis of discontinuation rates . Int Clin Psychopharmacol. 9:1994;47-53.
47. Song F., Freemantle N., Sheldon T.A., et al. Selective serotonin reuptake inhibitors meta-analysis of efficacy and acceptability . BMJ. 306:1993;683-687.
48. Lin E., Von Korff M., Katon W., et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1:1995;67-74.
49. Katon W., Von Korff M., Lin E., et al. Collaborative management to achieve treatment guidelines. JAMA. 273:1995;1026-1031.
50. Malt U.F., Robak O.H., Madsbu H.-P., Bakke O., Loeb M. The Norwegian naturalistic treatment study of depression in general practice (NORDEP)-I randomised double blind study . BMJ. 318:1999;1180-1184.